Navigation Links
Dual role in breast tissue for a protein involved in leukemia
Date:6/12/2009

Washington, DC - A protein known to play a role in growth of some types of leukemia appears to have a mixed function in breast cancer development, say researchers from the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC).

The findings, presented at the annual meeting of the Endocrine Society in Washington, DC, indicate that the function of this protein, known as Stat5a, may be different in developing breast cancer cells that are estrogen receptor-positive as compared to estrogen receptor-negative. When estrogen receptor levels were overexpressed, loss of Stat5a reduced development of a lobular type of preneoplasia. However, when estrogen receptor levels were normal, loss of Stat5a not only had no effect on reducing preneoplasia, but increased susceptibility to carcinogen-induced breast cancer. The results illustrate the importance of breast cancer heterogeneity when testing new therapeutic targets.

The researchers say Stat5a could be a target for treatment of leukemia, but add, "If Stat5a is to be used as a drug target for leukemia or other cancers, it is important to fully understand how altering its function impacts the breast, especially since it appears it may play different roles in different types of breast cancer," says the study's lead author, Anne Miermont, MS, a doctoral graduate student in tumor biology at Georgetown University Medical Center.

Stat5a is a member of the STAT family of proteins, which are key to regulating cell growth and differentiation. Because they have been found to be over-expressed in leukemia, Miermont and Priscilla Furth, MD, a professor of oncology, sought to see if they were important in breast cancer development. Estrogen receptors are over-expressed in more than half of human breast cancers, so the investigators set up studies to test if the function of Stat5a was the same or different in cells with estrogen receptor overexpression.

They found that Stat5a A is rather
'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Dioxins in food chain linked to breastfeeding ills
2. Wet ear wax and unpleasant body odors signal breast cancer risk
3. Breastfeeding duration and weaning diet may shape childs body composition
4. Lombardi scientist brings dream team breast cancer research effort to GUMC
5. Genetic testing for breast or ovarian cancer risk may be greatly underutilized
6. UNC study identifies genetic cause of most common form of breast cancer
7. IMPAKT -- Breast cancer conference highlights
8. Breast health center gives TGen new research opportunities
9. UC Davis researchers identify a protein that may help breast cancer spread, beat cancer drugs
10. Twin nanoparticle shown effective at targeting, killing breast cancer cells
11. Red wine vs. white? It makes no difference when it comes to breast-cancer risk

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)..., CINCINNATINew research presents strong evidence...ure to both outdoor traffic-related pollution and ...ngs than one or the other exposure alone. , En... Cincinnati (UC) College of Medicine have shown th...-related particles and indoor endotoxin during ear...
(Date:11/23/2009)..., TORONTO, November 23, 2009 - The time of day ...rding to a new paper produced by a research team l...ronto Scarborough,s vice-principal for research an... biology at the St. George campus. , Capitaliz... the poplar tree, the research team examined how p...
(Date:11/23/2009)..., Farmington, CT Current research suggests that ...disease. The related report by Nichols et al, "Un...t a New Class of TLR2 Ligands Capable of Enhancing... of The American Journal of Pathology . , Multi...tem attacks the brain and spinal cord, affects nea...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Time of day matters to thirsty trees, U of T researcher discovers 2Factors from common human bacteria may trigger multiple sclerosis 2Martek to Present at Upcoming Canaccord Adams Conference 52983 1Mathematical modeling predicts response to Herceptin 52980 1Mathematical modeling predicts response to Herceptin 52980 2Northwest Hospital Introduces Hyperbaric Oxygen Therapy 52978 1Northwest Hospital Introduces Hyperbaric Oxygen Therapy 52978 2
... CORVALLIS, Ore. Contrary to 40 years of convent...y in the journal Nature suggests that old growth...ue to absorb carbon dioxide from the atmosphere an...r, these old growth forests around the world are n...en considered of no significance in the national "...
... VIRGINIA KEY, Fla. -- The precise timing of the ...ring the past 4.5 billion years has been a subject...rincipal indicator of the amount of organic carbon...d is the ratio of the less abundant isotope of car...lants preferentially incorporate 12C, during perio...
... , Researchers studying a critical stage of pregna...e found a protein that is vital to the growth of n...this protein, which is produced in higher quantiti...kely to survive. , This is the first study to det...rogen spurs cell differentiation and blood-vessel ...
Other Biology News:Old growth forests are valuable carbon sinks 2Old growth forests are valuable carbon sinks 3University of Miami scientist uncovers miscalculation in geological undersea record 2Gap junction protein vital to successful pregnancy, researchers find 2
(Date:11/25/2009)..., ,, BOCA RATON, Fla., Nov. 25 /PRNewswi...l year. Not so for BodyLogicMD. The nation,s larg...ns specializing exclusively in medically supervise... physicians in its network since November 20...s to add more physician-owned centers, including o...
(Date:11/25/2009)... Nov. 25 Ardea Bioscienc...ry D. Quart, Pharm.D., president and chief executi... Annual Health Care Conference. , ,Presentation d...Health Care Conference,Date: Tuesday, Decembe...on: The New York Palace Hotel, New York, NY,Webca...
(Date:11/24/2009)... The New York investment bank KTA Capital,s clie... an AU$6.7 mil convertible note private placement ...acement was arranged by KTA Capital as Neuren,s ex... New York (PRWEB) November 23, 2009 -...ital, LLC ("KTA Capital") has announced ...
(Date:11/24/2009)...S, Nov. 24 Sigma-Aldrich...t the NASDAQ OMX conference on Tuesday, December 1...ested parties may listen via live audio broadcast ...or.sig m a a ldrich.com/ . Users can click t...bout Sigma-Aldrich: Sigma-Aldrich is a leading L...
Breaking Biology Technology:Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 4Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2
...g Research Institute Introduce New Research Base a... Diego , , SAN DIEGO, Feb. 11 Leading global bio...nd its affiliate Ferring Research Institute have o...ity located in Sorrento Valley, San Diego that wil...esearch and therapeutics. , , (Photo: http://w...
.... (OTC Bulletin Board: GOVX), an Atlanta-based, pu... human vaccines for diseases caused by HIV-1 (Huma...nts, today announced that Robert McNally, Ph.D., C...corporate update at the Eleventh Annual BIO CEO &a...Astoria Hotel, in New York. , , Dr. McNally prese...
...hronic Pain Indications , , LA JOLLA, Calif., Feb...TX ) today announced that oral administration of N...agonist, was safe and well-tolerated in healthy ma...ive consecutive days. , , "The successful complet... and tolerability of NGX426 when dosed over multip...
Other Biology Technology:Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix 2Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix 3Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix 4GeoVax Update Provided at the BIO CEO & Investor Conference 2009 2GeoVax Update Provided at the BIO CEO & Investor Conference 2009 3GeoVax Update Provided at the BIO CEO & Investor Conference 2009 4GeoVax Update Provided at the BIO CEO & Investor Conference 2009 5First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 2First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 3First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 4
...ptide sequence corresponding to Tyr89 Gly265 of m...recombinant soluble proform of MT1-MMP purified fr...fic activity of MT1-MMP catalytic domain is = 140 ... mol peptide (7-methoxycoumarin-4-yl)acetyl-Pro-Le...
...current power supply capable of producing up to 50...ce for PAGE, SDS-PAGE and DNA or RNA submarine gel...ng applications.A dual function 100-hour time can ...cally accrue elapsed time when operated in the pas...
Anti-Interferon-beta (IFNb) Monoclonal Antibody, Unconjugated from CHEMICON
...100, RVT400, RVT405DDA, RVT4104 and Universal Vacu...DA., A non-corrosive, odorless specially formulat...res ranging from -105 to +260 degrees Celsius. Cry... evaporate. Far superior to dry ice and acetone.,...
Biology Products: